We are a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. We have a proprietary gene therapy platform, which we refer to as the Skin TARgeted Delivery platform, or STAR-D platform, which we are initially using to develop treatments for rare or orphan dermatological indications. Source
No articles found.
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on ap...
InflaRx (Nasdaq: IFRX) is a clinical-stage biop...
Betterpath makes the benefit of health data ownership clear, reconciling crucial s...
Betterpath makes the benefit of health data own...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the ...
Motus GI Holdings, Inc. is a medical technology...
GEMSS North America is a leading developer, manufacturer & distributor of Digital ...
GEMSS North America is a leading developer, man...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage co...
AVROBIO, Inc., a leader in lentiviral-based gen...
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.